US FDA Approves New Diabetes Management Software
The US Food and Drug Administration (FDA) has approved the marketing for a diabetes management software created by Israel’s DreaMed Diabetes. (Reuters)
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Diabetes. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Diabetes and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Diabetes?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
The AI-based diabetes therapy software is called the Advisor Pro T1D Therapy Software.
The program is specially created for physicians to help their patients manage their type 1 diabetes who need uninterrupted glucose monitoring and use insulin pumps.
“Advisor Pro enables patients using CGM and an insulin pump to analyze data and recommend to their provider when a change in diabetes-care treatment is timely and needed.” DreaMed chief executive officer Eran Atlas said in a statement.
“Type 1 diabetes, managed with greater attention, leads to improved patient quality of life and reduced payer health-related costs,” he added.
Advisor Pro is hoped to benefit 500,000 type 1 diabetic patients in the US who regularly use pumps, according to the company. Aside from the US FDA approval, the software has been given the European Union regulatory approval in February of this year.
DreaMed has raised $6.5 million from investors including Russian billionaire Roman Abramovich, equity crowdfunding platform OurCrowd, and Medtronic – one of the world’s largest medical equipment development companies.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
